(Total Views: 619)
Posted On: 10/20/2020 9:51:39 AM
Post# of 153897
Indeed! Not to mention an in indictment of the failure of the regulatory system in the US.
Perhaps I missed this in my quick read of the articile , but I wish the author had been more emphatic about Leronlimab's safety profile saying that no serious or adverse side effects have been reported.
I feel this would help contrast Leronlimab against Rem and the other potential therapies.
IMO
Perhaps I missed this in my quick read of the articile , but I wish the author had been more emphatic about Leronlimab's safety profile saying that no serious or adverse side effects have been reported.
I feel this would help contrast Leronlimab against Rem and the other potential therapies.
IMO
(0)
(0)
